Free Trial

Zimmer Biomet's (ZBH) "Hold (C-)" Rating Reaffirmed at Weiss Ratings

Zimmer Biomet logo with Medical background

Key Points

  • Weiss Ratings has reaffirmed Zimmer Biomet's stock rating as "Hold (C-)," indicating a cautious stance from analysts regarding the company's performance.
  • Multiple analysts have provided varying ratings and price targets for Zimmer Biomet, with a consensus target price of $112.89 and nine analysts rating it as "Buy" or "Strong Buy."
  • Zimmer Biomet reported a quarterly earnings per share of $2.07, exceeding expectations and marking a 7% increase in revenue compared to last year.
  • Interested in Zimmer Biomet? Here are five stocks we like better.

Zimmer Biomet (NYSE:ZBH - Get Free Report)'s stock had its "hold (c-)" rating restated by stock analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other research analysts have also weighed in on the stock. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 18th. Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a "buy" rating and a $130.00 target price for the company. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Raymond James Financial lifted their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Rothschild Redb raised shares of Zimmer Biomet to a "strong-buy" rating in a research report on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $112.89.

Read Our Latest Stock Report on ZBH

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded down $0.74 during mid-day trading on Wednesday, hitting $98.32. The stock had a trading volume of 441,475 shares, compared to its average volume of 1,923,329. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The company has a 50 day moving average of $101.01 and a two-hundred day moving average of $98.54. Zimmer Biomet has a twelve month low of $89.22 and a twelve month high of $114.72. The firm has a market cap of $19.48 billion, a PE ratio of 23.92, a PEG ratio of 2.27 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period last year, the firm earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts predict that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds have recently made changes to their positions in the business. Czech National Bank increased its position in shares of Zimmer Biomet by 4.0% during the 3rd quarter. Czech National Bank now owns 50,313 shares of the medical equipment provider's stock worth $4,956,000 after purchasing an additional 1,952 shares in the last quarter. Country Club Bank raised its position in shares of Zimmer Biomet by 24.7% in the 3rd quarter. Country Club Bank now owns 59,943 shares of the medical equipment provider's stock valued at $5,891,000 after acquiring an additional 11,888 shares during the period. ST Germain D J Co. Inc. raised its position in shares of Zimmer Biomet by 12.3% in the 3rd quarter. ST Germain D J Co. Inc. now owns 127,931 shares of the medical equipment provider's stock valued at $12,601,000 after acquiring an additional 14,058 shares during the period. Canandaigua National Bank & Trust Co. acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $204,000. Finally, Sage Capital Advisors llc acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $906,000. Institutional investors and hedge funds own 88.89% of the company's stock.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Recommended Stories

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zimmer Biomet Right Now?

Before you consider Zimmer Biomet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.

While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.